Global Radiation Syndrome Therapeutics Market 2019-2023

The global radiation syndrome therapeutics market is forecasted to experience a meteoric rise by 2023 driven by the increasing collaborations between the major radiation syndrome therapeutic companies. Wondering how to make the most of this flourishing radiation syndrome therapeutics industry? Technavio’s extensive industry research report offers detailed insights that will allow you to take full advantage of the opportunities available to you. This study provides an extensive analysis by considering the evolving demographics and consumer behavior in the global radiation syndrome treatment market. It also examines the competitive landscape and some key radiation syndrome therapeutic companies including Amgen, Neumedicines, and Onconova Therapeutics.

What will the Radiation Syndrome Therapeutics Market Size be in 2019?

How will Rise in Nuclear Testing Influence Radiation Syndrome Therapeutics Market Growth?

Radiation syndrome treatment industry growth is expected to accelerate over the next five years, driven by increase in nuclear testing which is leading to a rise in cases of radiation poisoning and need for acute radiation syndrome treatment. An increase in nuclear testing in South-East Asia over the past few years has resulted in the rise in symptoms of radiation toxicity and exposure in nearby countries. Furthermore, various scientists and environmentalists believe that the growing rates of nuclear testing will cause significant damage to the environment and people around the location, which will fuel the demand for chronic radiation syndrome treatment. Technavio’s radiation syndrome treatment industry analysis reveals promising markets around the world.

Get a FREE Sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Which are the Key Markets for Radiation Syndrome Therapeutics?

The global radiation syndrome treatment market was dominated by the Americas with over 46% of the global market share, followed by EMEA and APAC. In addition, the Americas will drive 48% of the growth for the global radiation syndrome treatment industry, while EMEA and APAC are also predicted to contribute significantly to the incremental growth in the forecast period. The global radiation syndrome treatment market will witness the Americas registering the highest rate of growth during the forecast period, while EMEA will generate a higher CAGR than APAC.

Who are the Major Radiation Syndrome Therapeutics Vendors?

The global radiation syndrome treatment market is forecasted to become highly fragmented with the emergence of many international and regional radiation syndrome therapeutic companies who offer therapeutics for the treatment of HSC syndrome, CNS syndrome, GI syndrome, and cardiovascular syndrome caused by radiation poisoning. Some of the leading research institutions, biotechnology companies, and pharmaceutical players are collaborating for research on novel therapies to treat radiation toxicity. Many established radiation syndrome therapeutic companies are vying for their share of the global radiation syndrome treatment market, and the new players must differentiate themselves to gain vital traction over their peers.

This report offers a complete analysis of several radiation syndrome therapeutic companies, including:

• Amgen
• Neumedicines
• Onconova Therapeutics
• Partner Therapeutics
• Tonix Pharmaceuticals

We can help! Our analysts can customize this report to meet your requirements. Get in touch